Veratridine |
Catalog No.GC14730
One-Click Copy Product Info
|
Voltage-gated Na+ channel opener
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 71-62-5
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Voltage-gated Na+ channel opener; increases intracellular Ca2+ with no effect on the Na+/Ca2+ exchanger. Steroid-derived alkaloid neurotoxin. Increases membrane Na+ permeability and depolarizes excitable tissues.
Reference:
[1]. Purification, solubility and pKa of veratridine.
McKinney et al.
Anal.Biochem., 1986;153:33
[2]. Effects of Ca2+ channel antagonists on chromaffin cell death and cytosolic Ca2+ oscillations induced by veratridine.
Maroto et al.
Eur.J.Pharmacol., 1994;270:331
[3]. Mechanism of the persistant sodium current activator veratridine-evoked Ca2+ elevation: implication for epilepsy.
Fekete et al.
J.Neurochem., 2009;111:745
| Cell experiment [1]: | |
|
Cell lines |
HCT-116 colon cancer cells (expressing GFP-UBXN2A) |
|
Preparation method |
The solubility of this compound in DMSO is >10mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
20 and 40 μM, 24 hours |
|
Applications |
Veratridine is the main UBXN2A enhancer, increased UBXN2A protein levels in a dose-dependent manner. |
| Animal experiment [2]: | |
|
Animal models |
C57Bl/6N mice( HCT-116 cells expressing GFP-UBXN2A were injected into 6 to 8 week old nude female mice) |
|
Dosage form |
Intraperitoneal injection (IP), 0.125 mg/kg for 28 days |
|
Application |
Veratridine (VTD) was sufficient to induce UBXN2A protein levels, resulting in colon cancer cell death in UBXN2A- and mot-2-dependent manners. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Abdullah A, Sane S, Branick KA，et al.A plant alkaloid, veratridine, potentiates cancer chemosensitivity by UBXN2A-dependent inhibition of an oncoprotein, mortalin-2. Oncotarget. 2015 Sep 15;6(27):23561-81. |
|
| Cas No. | 71-62-5 | SDF | |
| Chemical Name | (3S,4S,4aS,6aS,6bS,8R,8aS,9S,9aS,12S,15aS,15bR,16aR,16bR)-4,6b,8,8a,9,15b-hexahydroxy-9,12,16b-trimethyldocosahydro-1H-4,16a-epoxybenzo[4,5]indeno[1,2-h]pyrido[1,2-b]isoquinolin-3-yl 3,4-dimethoxybenzoate | ||
| Canonical SMILES | O[C@@]([C@@]1([C@H](CN2[C@H]3CC[C@H](C)C2)[C@]4([C@@]3(C)O)O)O)(C[C@H]4O)[C@H]5[C@@]([C@@](CC[C@@H]6OC(C(C=C7OC)=CC=C7OC)=O)(C)[C@@H]8CC5)(C1)O[C@@]86O | ||
| Formula | C36H51NO11 | M.Wt | 673.79 |
| Solubility | <33.69mg/ml in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4841 mL | 7.4207 mL | 14.8414 mL |
| 5 mM | 296.8 μL | 1.4841 mL | 2.9683 mL |
| 10 mM | 148.4 μL | 742.1 μL | 1.4841 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 11 reference(s) in Google Scholar.)